is microdosing glp 1 effective glucagon‑like peptide‑1 (GLP‑1) receptor agonist therapy or safe for premenstrual syndrome? Are you curious about whether

Annals of Medicine and Surgery

One of the hallmarks in several neurodegenerative disorders in the progressive loss of glucose uptake in the brain, and among other effects, we saw that those with T2D had lower glucose uptake compared to overweight/obesity and the controls

WEIGHING THE GLP-1 MARKET

Rates of obesity nearly doubled between 1980 and 2008 worldwide, and more than half of all adults in the OECD region are now overweight, with 18% considered obese

FASEB J 2021;35:e21216

Individuals seeking medically guided weight loss Adults struggling with appetite control or cravings Those with a BMI in the overweight or obese range Individuals with insulin resistance or prediabetes (pending physician approval) Patients who have plateaued with diet and exercise alone People committed to combining medication with lifestyle changes Anyone wanting a structured, physician-led program with ongoing support Who Should Avoid GLP